Cargando…
JMJD6 orchestrates a transcriptional program in favor of endocrine resistance in ER+ breast cancer cells
High expression of Jumonji domain containing protein 6 (JMJD6) is strongly associated with poor prognosis in estrogen receptor positive (ER+) breast cancer. We overexpressed JMJD6 in MCF7 cells (JOE cells) and performed RNA-seq analysis. 76% of differentially expressed genes (DEGs) overlapped with E...
Autores principales: | Das, Partha, Gupta, Aritra, Desai, Kartiki V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678079/ https://www.ncbi.nlm.nih.gov/pubmed/36419768 http://dx.doi.org/10.3389/fendo.2022.1028616 |
Ejemplares similares
-
Pathways to Endocrine Therapy Resistance in Breast Cancer
por: Haque, Md. Moquitul, et al.
Publicado: (2019) -
Both EZH2 and JMJD6 regulate cell cycle genes in breast cancer
por: Biswas, Antara, et al.
Publicado: (2020) -
JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer
por: Lee, Yi Fang, et al.
Publicado: (2012) -
Erratum to: JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer
por: Lee, Yi Fang, et al.
Publicado: (2017) -
JMJD6 Regulates ERα Methylation on Arginine
por: Poulard, Coralie, et al.
Publicado: (2014)